SG11201708084PA - Ribociclib tablet - Google Patents

Ribociclib tablet

Info

Publication number
SG11201708084PA
SG11201708084PA SG11201708084PA SG11201708084PA SG11201708084PA SG 11201708084P A SG11201708084P A SG 11201708084PA SG 11201708084P A SG11201708084P A SG 11201708084PA SG 11201708084P A SG11201708084P A SG 11201708084PA SG 11201708084P A SG11201708084P A SG 11201708084PA
Authority
SG
Singapore
Prior art keywords
ribociclib
tablet
ribociclib tablet
Prior art date
Application number
SG11201708084PA
Other languages
English (en)
Inventor
Bindhumadhavan Gururajan
Arnaud Grandeury
Rui Costa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201708084P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201708084PA publication Critical patent/SG11201708084PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201708084PA 2015-04-16 2016-04-14 Ribociclib tablet SG11201708084PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
SG11201708084PA true SG11201708084PA (en) 2017-10-30

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708084PA SG11201708084PA (en) 2015-04-16 2016-04-14 Ribociclib tablet

Country Status (29)

Country Link
US (3) US10799506B2 (de)
EP (2) EP4197530A1 (de)
JP (1) JP2018514523A (de)
KR (1) KR20170137101A (de)
CN (2) CN107530292B (de)
AR (1) AR104257A1 (de)
AU (3) AU2016248017A1 (de)
BR (1) BR112017021283A2 (de)
CA (1) CA2982425C (de)
CL (1) CL2017002593A1 (de)
CO (1) CO2017010510A2 (de)
DK (1) DK3283058T3 (de)
EA (1) EA201792290A1 (de)
EC (1) ECSP17075052A (de)
ES (1) ES2938261T3 (de)
FI (1) FI3283058T3 (de)
HR (1) HRP20230053T1 (de)
HU (1) HUE061213T2 (de)
IL (1) IL254818A0 (de)
MX (1) MX2017013350A (de)
PE (1) PE20180035A1 (de)
PH (1) PH12017501820A1 (de)
PL (1) PL3283058T3 (de)
PT (1) PT3283058T (de)
SG (1) SG11201708084PA (de)
SI (1) SI3283058T1 (de)
TN (1) TN2017000422A1 (de)
TW (1) TW201642864A (de)
WO (1) WO2016166703A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016248017A1 (en) * 2015-04-16 2017-10-19 Novartis Ag Ribociclib tablet
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
CA3164617A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
CA3164619A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
CA3187241A1 (en) * 2020-08-03 2022-02-10 Krishna Murthy Bhavanasi Pharmaceutical compositions comprising ribociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
WO2023144684A1 (en) 2022-01-25 2023-08-03 Novartis Ag Ribociclib pharmaceutical compositions
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
EP0771339B1 (de) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Trockene beschichtungszusammensetzung, die einen feuchtigkeitssperrenden film bildet, verfahren zur beschichtung von substraten mit dieser zusammensetzung und damit beschichtete pharmazeutische tabletten
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
DK2331547T3 (da) 2008-08-22 2014-11-03 Novartis Ag Pyrrolopyrimidinforbindelser som CDK-inhibitorer
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
AU2011358840B2 (en) * 2011-02-11 2017-05-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
MX2015000572A (es) * 2012-07-13 2015-09-23 Gtx Inc Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
EP2742940B1 (de) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane Fumarat zur einmal, zweimal oder dreimal täglichen Verabreichung
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
SG10201906270VA (en) * 2013-03-21 2019-08-27 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
EP2810644A1 (de) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen
AU2016248017A1 (en) * 2015-04-16 2017-10-19 Novartis Ag Ribociclib tablet
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
CL2017002593A1 (es) 2018-05-18
CO2017010510A2 (es) 2018-03-20
ECSP17075052A (es) 2018-02-28
KR20170137101A (ko) 2017-12-12
SI3283058T1 (sl) 2023-03-31
BR112017021283A2 (pt) 2018-06-26
FI3283058T3 (fi) 2023-03-01
AU2020250190A1 (en) 2020-11-05
AU2019201929A1 (en) 2019-04-11
CA2982425A1 (en) 2016-10-20
MX2017013350A (es) 2018-01-25
EP3283058B1 (de) 2022-11-16
AR104257A1 (es) 2017-07-05
TN2017000422A1 (en) 2019-01-16
IL254818A0 (en) 2017-12-31
HUE061213T2 (hu) 2023-05-28
WO2016166703A1 (en) 2016-10-20
US20200390771A1 (en) 2020-12-17
EP3283058A1 (de) 2018-02-21
CA2982425C (en) 2023-10-31
JP2018514523A (ja) 2018-06-07
TW201642864A (zh) 2016-12-16
PL3283058T3 (pl) 2023-03-20
PH12017501820A1 (en) 2018-04-23
US20180071292A1 (en) 2018-03-15
PE20180035A1 (es) 2018-01-09
EA201792290A1 (ru) 2018-02-28
AU2022215155A1 (en) 2022-09-01
CN107530292B (zh) 2022-11-01
DK3283058T3 (da) 2023-02-13
AU2019201929B2 (en) 2020-07-09
CN115554257A (zh) 2023-01-03
AU2016248017A1 (en) 2017-10-19
CN107530292A (zh) 2018-01-02
US20230104792A1 (en) 2023-04-06
EP4197530A1 (de) 2023-06-21
ES2938261T3 (es) 2023-04-05
US10799506B2 (en) 2020-10-13
HRP20230053T1 (hr) 2023-03-03
PT3283058T (pt) 2023-02-03

Similar Documents

Publication Publication Date Title
GB201707959D0 (en) No details
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
AU356804S (en) Tablet
DK3250592T3 (en) Anti-transthyretin-antistoffer
SG11201705976UA (en) Cryoneedle
IL254818A0 (en) Ribociclib tablet
GB201706130D0 (en) No details
GB201612542D0 (en) no details
GB201615071D0 (en) No details
HK1249857A1 (zh) 片劑
GB201709180D0 (en) No details
DK3272750T3 (en) Morphinan-derivat
GB201420300D0 (en) Tablet
AU361999S (en) Ballustrade
DK3133099T3 (en) Polymermodificeret polyoldispersion
GB201616225D0 (en) No details
DK3282866T3 (en) Proteinfibre
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB201708207D0 (en) No details
GB201702336D0 (en) No details
AU356801S (en) Tablet
EP3431079C0 (de) Tablette
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201511252D0 (en) Tablet